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Colorectal cancer (CRC) is the third most common cancer world-
wide and has a high mortality rate. Despite recent advances in
diagnostic modalities for CRC, it also act as a major cause of
cancer death in afﬂuent countries with over one million cases
worldwide and a disease-speciﬁc mortality of approximately 33%
in the developed world1. Chemotherapy is one of the commonly
used strategies in CRC treatment. Conventional chemotherapeutic
drugs such as cisplatin (CDDP), adriamycin and 5-ﬂuorouracil (5-
FU) often have severe side effects that limit their efﬁcacy2.
Therefore, there is a critical need to develop more effective
strategies for the cancer therapy. Combination therapy with
multiple drugs or modalities is a common practice in the treatment
of cancers, which can achieve therapeutic effects greater than those
of provided by a single drug or modality, and can reduce the side
effects and resistance to drugs.
RasGAP is a regulator of Ras and Rho GTP-binding proteins.
It can induce both anti- and pro-apoptotic signals depending on the
extent of its cleavage by caspase3,4. RasGAP is a substrate of
caspase; when cleaved at position 455, N-terminal fragment of the
production protects cells from apoptosis in a Ras/PI3K/Akt-
dependent manner5. As increase of caspase activity, the
N-terminal fragment can further cleave into two smaller fragments
at position 157 which can induce apoptosis4 and markedly reduce
Akt activity. A synthetic peptide TAT-RasGAP317–326 was
found to efﬁciently increase the extent of apoptosis induced by a
variety of genotoxins and other anti-cancer treatments in several
tumor cell lines both in vitro and in vivo3,6–8, which depends on
functional p53 and PUMA (p53-upregulated modulator of apop-
tosis)9. Cui et al.10 reported that two novel peptides derived from
RasGAP SH3 domain with cytotoxicity on tumor cells showed an
obvious sensitizing effect on CDDP. However, they had no
signiﬁcant effects on normal cells, but the mechanism was not
clear. Previously, we have reported two peptides showed promis-
ing anti-tumor activity in vitro and in vivo through down-
regulation of G3BPs11,12. G3BPs proteins are dramatically over-
expressed in human cancers, especially in breast, head and neck,
colon, and lung13–15. G3BPs are involved in a variety of growth-
related signaling pathways that are involved in carcinogenesis and
metastasis16–18, including NF-κB, Ras signaling and the ubiquitin
proteasome system13,19–21.
In this study, we demonstrated a new synthetic peptide GAP159
derived from RasGAP SH3 domain enhanced the cytotoxicity and
apoptotic potential of CDDP in human colon cancer HCT116
cells. The combination of GAP159 and CDDP showed a sig-
niﬁcant synergy in HCT116 cells. We found GAP159 could down-
regulate G3BPs, and several G3BP-related molecules of transduc-
tion signaling pathways were detected including ERK, NF-κB and
Akt pathways. The antitumor effects of GAP159 alone or
combined with CDDP were also evaluated in mouse colon tumor
CT26 model.2. Materials and methods
2.1. Peptide synthesis
GAP159, a cell-permeable peptide, was synthesized at Wuhan
KatyGen Pharmaceuticals (Hubei, China). The peptides were
dissolved in deionized water at a ﬁnal concentration of 10 mmol/L
and stored at 20 1C until further use.2.2. Cell culture and reagents
Human colon carcinoma HCT116 cells were purchased from
ATCC (Manassas, VA, USA). Cells were grown in DMEM
(Gibco, Grand Island, USA) supplemented with 10% fetal bovine
serum, 2 mmol/L L-glutamine, and 1% penicillin–streptomycin at
37 1C in the presence of 5% CO2. Cisplatin (Sigma-Aldrich, St
Louis, MO, USA) was diluted in PBS at a ﬁnal concentration of
20 mmol/L and stored at 20 1C.2.3. MTT assays
HCT116 cells were seeded in 96-well plates at a density of 3 103
cells/well in 200 μL medium. Then the cells were treated with
various concentrations of GAP159 alone or combined with CDDP.
After drug exposure for indicated hours, the MTT solution (5 g/L)
was added to the plates. The cells were incubated at 37 1C for
another 4 h. The formazan, which is derived from MTT by living
cells, was dissolved in 150 μL DMSO per well, and the absor-
bance was detected at 570 nm. All MTT experiments were
performed in triplicate and repeated at least 3 times. The
percentage of cytotoxicity was calculated as follows: cytotoxicity
(%)¼ [(1OD570 of experimental well)/OD570 of control
well] 100%.2.4. Terminal deoxynucleotidyl transferase-mediated dUTP nick
end labeling (TUNEL) assay
Cells were treated with 10 μmol/L and 30 μmol/L GAP159 alone
or combined with 10 μmol/L CDDP. TUNEL staining was
performed in situ using the DeadEnd ﬂuorometric TUNEL system
kit (Promega, Madison, Wisconsin, USA) according to the
manufacturer's protocol. The images were captured by an image
analysis system (Eclipse TE2000-U, Nikon, Japan). The number of
TUNEL positive cells was divided by the total number of cells to
determine the percentage of apoptosis.2.5. Western blot analysis
Whole cell lysates were used for immunoblotting as previously
described22. Brieﬂy, cells were washed with cold PBS, and then
lysed with RIPA lysis buffer containing protease and phosphatase
inhibitor. Floating cells or cell fragments were collected and lysed
with the above lysates. Protein concentrations were determined by
Bradford assay. Equal amounts of protein were separated by SDS-
PAGE and transferred to polyvinylidene diﬂuoride membrane
(Millipore Corp., Bedford, MA, USA). Membranes were blocked
in TBST containing 5% nonfat skim milk at room temperature for
2 h and probed with primary antibodies overnight at 4 1C. Then
the membranes were blotted with an appropriate horseradish
peroxidase-linked secondary antibody. Electochemiluminescence
was performed according to the manufacturer's instructions with
ChemiImager 5500 imaging system (Alpha Innotech Co., CA,
USA). Antibodies against Akt, phospho-Akt (Ser423), ERK and
phospho-ERK were from Cell Signaling Technology (Danvers,
MA, USA). G3BP2 was from Abcam (Cambridge, MA, USA),
and anti-β-actin was from Sigma (St Louis, MO, USA). Other anti-
G3BP1, HRP-linked goat anti-rabbit and anti-mouse secondary
antibodies were from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
Figure 1 GAP159 down-regulates the level of G3BP1 and G3BP2
proteins. Cells were treated with GAP159 for 48 h; G3BP1 and
G3BP2 proteins were detected by Western blot.
H. Zhang et al.1302.6. In vivo tumor mouse model
Male BALB/c mice (Institute for Experimental Animals, Chinese
Academy of Medical Sciences & Peking Union Medical College)
were injected with 1.5 million mouse colon carcinoma CT26 cells
subcutaneously on the right ﬂank. The following day and there-
after daily for GAP159 and every other day for CDDP, the mice
were injected intraperitoneally with PBS, 10 mg/kg, 20 mg/kg and
40 mg/kg of GAP159, 1 mg/kg CDDP, or a combination of
GAP159 and CDDP. After 11 days, all mice were weighed and
sacriﬁced, and the tumors were excised. Tumors were weighed,
and the mean tumor weight was calculated. The mean treated
tumor weight/mean control tumor weight  100% is subtracted
from 100% to give the tumor growth inhibition (TGI) for each
group.
2.7. Analysis of drug interaction
The coefﬁcient of drug interaction (CDI) was used to analyze the
synergistically inhibitory effect of the drug combination23. CDI
was calculated as follows: CDI¼AB/(AB). AB is the ratio of the
two-drug combination group to the control group, and A or B is the
ratio of the single drug group to the control group. Therefore,
CDIo1 indicates synergism, CDIo0.7 indicates a signiﬁcantly
synergistic effect, CDI¼1 indicates additivity, and CDI41
indicates antagonism.
2.8. Statistical analysis
Data were described as means7SD of the indicated number of
separate experiments. A one-way analysis of variance was carried
out for multiple comparisons. If there was signiﬁcant variation
between treatment and control groups, the mean values were
compared by using student's t-test. P-values less than 0.05 were
considered signiﬁcant.Figure 2 GAP159 inhibits HCT116 cell growth. A: GAP159
synergistically enhanced the inhibitory effects of CDDP on HCT116
cells (#Po0.05 vs CDDP); B: CDI value of co-treatment of GAP159
and CDDP.3. Results
3.1. Down-regulation of G3BP proteins by GAP159
According to the structure-base design of peptide against G3BP by
Cui et al.10, we have reported two peptides showing promising
anticancer activities alone or combined with CDDP, and revealed
the mechanisms. Our cooperator designed a new peptide GAP159
through amino acid substitution, which, theoretically, had strong
interaction with G3BP and was more stable. Previously, we found
that down-regulation of G3BP by peptide or siRNA could inhibit
cancer cell proliferation and induce apoptosis11. To ﬁgure out
whether the new peptide GAP159 had the same effect on G3BP
protein, we treated HCT116 cells with GAP159 alone or combined
with CDDP. Western blot results showed that GAP159 could
signiﬁcantly reduce the level of G3BP1 and G3BP2 proteins
(Fig. 1). CDDP alone had no effect on G3BP proteins.
3.2. Inhibitory effect of GAP159 and CDDP on HCT116 cells
To explore whether GAP159 might be a potential therapeutic
agent against HCT116 cells, we investigated the anti-proliferative
activity of GAP159 with or without CDDP. After drug exposure,
cell proliferation was determined by MTT assay (Fig. 2A).GAP159 alone inhibited proliferation of HCT116 cells in a dose
and time-dependent manner. For 48 h treatment, the inhibition
rates of 10 μmol/L and 30 μmol/L GAP159 were 21.3% and
46.34%, respectively. When treated the cells with 30 μmol/L
GAP159, the inhibition rates of 24, 48 and 72 h treatment were
39.33%, 46.34%, 54.46%, respectively. The combination of
GAP159 and CDDP showed signiﬁcant anti-proliferative effects
on HCT116 cells as compared with GAP159 or CDDP alone
(Po0.05). For 72 h treatment, the inhibitory rates of 10 μmol/L
Figure 3 GAP159 enhances CDDP induced apoptosis. A: Co-treatment of GAP159 and CDDP induced apoptosis detected by TUNEL assay; B:
quantiﬁcation of TUNEL positive cells (nPo0.05 vs Control, #Po0.05 vs CDDP); C: the changes of caspase-3/7 activity in GAP159 and/or
CDDP treated cells. The results are mean7SD of three individual experiments.
GAP159 enhances cisplatin-induced cytotoxicity and apoptosis 131and 30 μmol/L GAP159 combined with CDDP were 78.83% and
88.33%, respectively.
CDI was used to evaluate the nature of the interaction. As
shown in Fig. 2B, the CDI values of all combination situations are
under 1. For 48 h treatment, the CDI values were 0.91 and 0.75.
For 72 h exposure, the CDI values were 0.81 and 0.7. These
results indicate that GAP159 synergistically enhances CDDP-
induced cytotoxicity in HCT116 cells.3.3. Enhancement of CDDP-induced apoptosis by GAP159
To determine whether GAP159 potentiated CDDP-induced apop-
tosis, we employed TUNEL staining assay (Fig. 3A). As shown in
Fig. 3B, the percentage of TUNEL positive cells is increased from
1.1% in control cells to 6.7% and 12.6% in GAP159-treated cells.
GAP159 also increased CDDP-induced TUNEL positive cells from
3.8% to 22.7% and 34.7% (Fig. 3B). This result is conﬁrmed by
caspase-3/7 activity assay, which showed GAP159 markedly
enhanced CDDP induced caspase-3/7 activities (Fig. 3C). Taken
together, the results indicate that GAP159 enhances CDDP-induced
apoptosis.3.4. Inhibition of Akt, ERK and NF-κB activations by GAP159
Previously, we found that down-regulation of G3BP by peptides
and siRNAs could impair Ras activity and inhibit downstream
signaling pathways11,12. Therefore, GAP159 may affect the Ras
pathways including ERK and NF-κB. In addition, extraordinary
activation of ERK cascades by CDDP antagonizes apoptosis24. So,
we detected the effect of GAP159 on CDDP induced activations of
ERK and NF-κB. Western blot results showed that GAP159
clearly inhibited CDDP induced ERK activity and had no
signiﬁcant effect on total ERK protein levels (Fig. 4). We also
determined if the GAP159 modulated Akt activity and sensitized
HCT116 cells to CDDP. Fig. 4 shows that GAP159 inhibits Akt
phosphorylation, and has no effect on total Akt expression. It has
been reported that NF-κB activity could be modulated by ERK and
Akt25. We also found that GAP159 signiﬁcantly down-regulated
NF-κB (Fig. 4).3.5. GAP159 enhanced antitumor activity of CDDP in vivo
In vivo experiment was employed to conﬁrm the synergism of
GAP159 combined with CDDP. The antitumor effect evaluation
H. Zhang et al.132was carried out using mouse colon tumor CT26 model established
in BALB/c mice. The mice were intraperitoneally injected with
PBS, 10 mg/kg, 20 mg/kg and 40 mg/kg GAP159 once per day,
and 1 mg/kg of CDDP every other day. As evaluated on day 11
(Table 1), the inhibitory effect of 1 mg/kg CDDP was 39.2%, and
10 mg/kg, 20 mg/kg and 40 mg/kg GAP159 showed slight ther-
apeutic efﬁcacy with 10.6%, 18.4% and 33.5% TGI, respectively.
As shown in Table 1, the combinations of CDDP with 10 mg/kg,
20 mg/kg and 40 mg/kg GAP159 were markedly displayed anti-
tumor inhibitory effects with 51.3%, 65.5% and 69.8% TGI,
respectively. These results show that GAP159 could enhance the
activity of CDDP in vivo.Figure 4 Effects of GAP159 on Akt, ERK and NF-κB. A: Cells
were treated with GAP159 in the absence or presence of CDDP for
48 h; B: quantiﬁcation of protein levels. The protein levels were
detected by Western blot.
Table 1 Combination treatment of GAP159 and CDDP signiﬁcantly
Groups Dosage (mg/kg) No. of mice (begin/end) Body weig
Control – 10/10 þ0.44
CDDP 1 10/10 1.22
GAP159 10 10/10 0.71
20 10/10 0.64
40 10/10 0.89
GAP159 10þ1 10/10 1.16
þCDDP 20þ1 10/10 1.18
40þ1 10/10 1.67
aPo0.05 vs control group.
bPo0.05 vs CDDP group.4. Discussion
Chemotherapy drug CDDP is widely used for the treatment of
many malignancies, including ovarian, bladder, cervical, head and
neck, and colon cancer26. The cytotoxicity of CDDP is believed to
be the result of the formation of platinum–DNA adducts. Despite
the great efﬁcacy in treating certain kinds of cancers, chemother-
apy drugs could also damage other normal cells which cause some
side effects. Speciﬁc sensitization of tumor cells to the action of
chemotherapy drugs would reduce the efﬁcacious doses of
chemotherapy drugs to be used in patients, diminish the detri-
mental side effects on normal tissues and enhance the efﬁcacy of
chemotherapeutic treatments, which was called combination che-
motherapy. In the present study, we report a synthetic peptide
GAP159 strongly sensitized HCT116 cells to CDDP-induced
cytotoxicity and apoptosis.
G3BP were ﬁrst identiﬁed as a RasGAP SH3 domain binding
protein, and the NTF2-like domain was responsible for its binding
to RasGAP27. Parker et al.28 developed a monoclonal antibody
directed against the NTF2-like domain of G3BP, showing a
speciﬁc effect in the therapy for the G3BP-related tumors. Cui
et al.10 established a G3BP NTF2-like domain and RasGAP SH3
domain interaction model, and designed two peptides showing an
obvious sensitizing effect to CDDP. According to this model, our
cooperators designed a new peptide GAP159 through amino acid
substitution. Previously, we found that down-regulation of G3BP
by peptides or siRNAs could inhibit cancer cell growth and induce
apoptosis. In this study, likewise, we found GAP159 signiﬁcantly
down-regulated the G3BP1 and G3BP2 protein levels, and showed
promising anti-proliferation effect in vitro and in vivo. Meanwhile,
GAP159 alone or combined with CDDP induced HCT116 cell
apoptosis, indicating a signiﬁcant synergistic effect.
Ras and PI3K/AKT signaling pathways play an important role
in cell survival, proliferation and apoptosis, and are critical for the
progression of CRC29,30. Recent studies31,32 reported that activa-
tion of the PI3K pathway contributed to the resistance to MAPK
kinase (MEK) inhibitors in CRC cells, suggesting that the therapy
with a combination of PI3K and MEK inhibitors may be a more
effective treatment for cancers33. Our results showed that inhibi-
tion of ERK and Akt enhanced CDDP-induced anti-proliferation
effect12. Interaction of RasGAP and G3BP occurs only in growing
cells and both proteins are recruited to activate Ras19,27, suggesting
that G3BP could participate in Ras signal pathway through
RasGAP. Previously, we found that knockdown of G3BP inhibited
ERK and Akt activities11. Herein, GAP159 down-regulatedsuppressed the tumor growth of BALB/c mice bearing colon CT26.
ht change (g) Tumor weight (mean7SD) TGI (%) CDI
1.5870.44 – –
0.9670.19a 39.2 –
1.4170.47 10.6 –
1.2970.29a 18.4 –
1.0570.22a 33.5 –
0.7770.29a 51.3 0.89
0.5570.20a,b 65.5 0.69
0.4870.16a,b 69.8 0.74
GAP159 enhances cisplatin-induced cytotoxicity and apoptosis 133G3BPs, and inhibited the ERK and Akt phosphorylation. NF-κB
transcription factor is an important factor implicated in regulating
cell survival and apoptosis. Anti-cancer drugs induced NF-κB
activation attenuated their antitumor activity34. CDDP-induced
activation of ERK and NF-κB played an important role in
chemoresistance35,36. In our study, GAP159 inhibited ERK and
Akt activities and reduced NF-κB, which might contribute to the
synergistic effect of co-treatment of GAP159 and CDDP.
In summary, GAP159 could down-regulate G3BP1 and G3BP2
proteins, and sensitize HCT116 cells to CDDP induced anti-
proliferation and apoptosis. GAP159-induced the suppression of
ERK and Akt, and the decrease of NF-κB contributed to this
synergism. Taken together, our results show that GAP159
synergistically enhances CDDP-induced cytotoxicity, suggesting
that the combination of GAP159 and chemotherapy drugs might
be a promising strategy for cancer therapy.Acknowledgments
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